DNA repair dysregulation from cancer driver to therapeutic target
NJ Curtin - Nature Reviews Cancer, 2012 - nature.com
Dysregulation of DNA damage repair and signalling to cell cycle checkpoints, known as the
DNA damage response (DDR), is associated with a predisposition to cancer and affects …
DNA damage response (DDR), is associated with a predisposition to cancer and affects …
DNA methylation profiling in the clinic: applications and challenges
H Heyn, M Esteller - Nature Reviews Genetics, 2012 - nature.com
Abstract Knowledge of epigenetic alterations in disease is rapidly increasing owing to the
development of genome-wide techniques for their identification. The ever-growing number …
development of genome-wide techniques for their identification. The ever-growing number …
DNA methyltransferases, DNA damage repair, and cancer
B Jin, KD Robertson - Epigenetic alterations in oncogenesis, 2012 - Springer
The maintenance DNA methyltransferase (DNMT) 1 and the de novo methyltransferases
DNMT3A and DNMT3B are all essential for mammalian development. DNA methylation …
DNMT3A and DNMT3B are all essential for mammalian development. DNA methylation …
Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer
GC Hon, RD Hawkins, OL Caballero, C Lo… - Genome …, 2012 - genome.cshlp.org
While genetic mutation is a hallmark of cancer, many cancers also acquire epigenetic
alterations during tumorigenesis including aberrant DNA hypermethylation of tumor …
alterations during tumorigenesis including aberrant DNA hypermethylation of tumor …
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome …
P Bady, D Sciuscio, AC Diserens, J Bloch… - Acta …, 2012 - Springer
The methylation status of the O 6-methylguanine-DNA methyltransferase (MGMT) gene is an
important predictive biomarker for benefit from alkylating agent therapy in glioblastoma …
important predictive biomarker for benefit from alkylating agent therapy in glioblastoma …
[HTML][HTML] Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance
RH Wilting, JH Dannenberg - Drug Resistance Updates, 2012 - Elsevier
Resistance of cancer cells to chemotherapeutics and emerging targeted drugs is a
devastating problem in the treatment of cancer patients. Multiple mechanisms contribute to …
devastating problem in the treatment of cancer patients. Multiple mechanisms contribute to …
miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression
Genome-wide microRNA (miRNA) profiling of 82 glioblastomas demonstrated that miR-181d
was inversely associated with patient overall survival after correcting for age, Karnofsky …
was inversely associated with patient overall survival after correcting for age, Karnofsky …
DNA methylation based biomarkers: practical considerations and applications
AH Kit, HM Nielsen, J Tost - Biochimie, 2012 - Elsevier
A biomarker is a molecular target analyzed in a qualitative or quantitative manner to detect
and diagnose the presence of a disease, to predict the outcome and the response to a …
and diagnose the presence of a disease, to predict the outcome and the response to a …
O6-Methylguanine-DNA methyltransferase in glioma therapy: Promise and problems
JR Silber, MS Bobola, A Blank… - Biochimica et Biophysica …, 2012 - Elsevier
Gliomas are the most frequent adult primary brain tumor, and are invariably fatal. The most
common diagnosis glioblastoma multiforme (GBM) afflicts 12,500 new patients in the US …
common diagnosis glioblastoma multiforme (GBM) afflicts 12,500 new patients in the US …
Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma
G Minniti, G Lanzetta, C Scaringi, P Caporello… - International Journal of …, 2012 - Elsevier
PURPOSE: Radiotherapy (RT) and chemotherapy may prolong survival in older patients
(age≥ 70 years) with glioblastoma multiforme (GBM), although the survival benefits remain …
(age≥ 70 years) with glioblastoma multiforme (GBM), although the survival benefits remain …